Corona virus vaccine in Germany developer Producer BioNTech reported a whopping 10.3 billion euros ($11.5 billion) in profits. in earnings in In 2021, up from 15.2 million euros ($17 million) year before.
The development of the vaccine developed together or together with American pharmaceutical giant Pfizer Inc first approved to counter the virus, it has had a “critical impact.” on human health and global economyBioNTech CEO Ugur Sahin said in a permit.
The company delivered 2.6 billion doses of “Kumernati” vaccine on messenger RNA (mRNA) technology in 2021, withdraw in Revenues of 19 billion euros in the operation.
BioNTech Ventures Vaccine Revenue in 2022 to reach between 13 billion and 17 billion euros, and aims to pump up to 1.5 billion euros research And the development. signed orders for The company said deliveries in 2022 have now reached 2.4 billion doses.
Omicron vaccine currently in Works, while the pharmaceutical company also Looking to develop treatments for Malaria and tuberculosis are among other diseases.
The rise of The small The biotech company had a tangible impact on German economy with Economists estimated this earlier year acquired by the company for about 0.5% of all economic activity in 2021.
revenue also Translated into a major boost for the government’s own vaults, with BioNTech pays 4.8 billion euros in tax in 2021, according to the company.
BioNTech said it will launch 1.5 billion euros share buy-back program over The next two years and pay out a cash Dividend of 2 euros per share.
